Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 2Melanoma 2Glioma 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasm Metastasis 1Multiple Myeloma 1Limited Stage Small Cell Lung Cancer 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 40Carboplatin 34Bevacizumab 29liposomal doxorubicin 20Specimen Handling 18Taxes 17olaparib 16Magnetic Resonance Spectroscopy 16pembrolizumab 15Gemcitabine 15Topotecan 13Immunoglobulin G 11Disulfides 11Biopsy 11mirvetuximab soravtansine 8niraparib 7Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Glucose × 1 year × Clear all
NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡